Pathogen and Pathogenesis of Amebiasis
Amebiasis is caused by the dysenteric amoeba (Entamoeba histolytica). Inside the human body and in the external environment, this parasite exists in two main forms:
- Cysts: The survival stage in the external environment. This is the infective form that ensures transmission.
- Trophozoites (vegetative forms): The active stage. They inhabit the intestinal lumen but are capable of invading the intestinal wall or migrating hematogenously to the liver.
Upon invading the bowel wall, trophozoites cause lysis and destruction of host tissues. They multiply in the submucosa (ranging from the surface epithelium to the muscular layer). The pathogen is characterized by lateral spread in tissues, leading to deep ulceration and the risk of bowel perforation. Clinically, the infection can manifest as asymptomatic carriage, invasive colitis (amebic dysentery), or metastatic lesions (most commonly liver abscesses).
Classification of Drugs by Site of Action
Depending on the tissues where a drug achieves therapeutic concentration, antiamebic agents are divided into several groups:
- Universal amebicides (metronidazole, ornidazole). They destroy vegetative forms of the parasite regardless of localization (intestine, liver, and other organs), but are completely ineffective against cysts.
- Tissue amebicides. They act selectively. For example, emetine (an ipecac alkaloid) works in the bowel wall and liver, while chloroquine works exclusively in the liver, making it the drug of choice for treating amebic liver abscesses.
- Lumen (contact) amebicides (diloxanide). They work solely within the intestinal lumen. Diloxanide is used as an insoluble ester (diloxanide furoate).
Pharmacology of Metronidazole and its Analogues
Metronidazole is the drug of choice for invasive forms of amebiasis. Structurally, it is a prodrug. To acquire cytotoxic properties, the nitro group must be reduced inside the parasite cell. This bioactivation process requires a high negative redox potential, which is characteristic of anaerobes and protozoa (microaerophiles). The reduced form of the drug binds to DNA, cell membranes, and proteins of the amoeba, causing severe cellular damage and death.
Application Features:
- Route of administration: Most commonly orally, though intravenous and rectal routes are also available.
- Side effects: Dyspeptic disorders, characteristic bitter metallic taste in the mouth.
- Drug interactions: The drug inhibits acetaldehyde dehydrogenase. If a patient consumes alcohol during treatment, ethanol oxidation stops at the acetaldehyde stage, resulting in a disulfiram-like reaction with severe intoxication.
A structural analogue of metronidazole is tinidazole (a second-generation nitroimidazole). It is also effective against a wide range of protozoa and is used in amebiasis, giardiasis, and vaginal trichomoniasis.
Pharmacotherapy Strategy
The choice of treatment regimen always depends on the clinical form of the disease and the stage of invasion:
- Acute invasive intestinal amebiasis and liver involvement: Therapy is strictly two-stage. First, a systemic amebicide (metronidazole or tinidazole) is administered to eradicate tissue forms. This is invariably followed by a luminal amebicide (diloxanide) to eliminate residual parasites from the intestinal lumen.
- Chronic amebiasis and asymptomatic carriage: Monotherapy with a luminal agent (diloxanide) is sufficient.